334 related articles for article (PubMed ID: 25188323)
1. Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales.
Linton A; Pavlakis N; O'Connell R; Soeberg M; Kao S; Clarke S; Vardy J; van Zandwijk N
Br J Cancer; 2014 Oct; 111(9):1860-9. PubMed ID: 25188323
[TBL] [Abstract][Full Text] [Related]
2. Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy.
Kao SC; Klebe S; Henderson DW; Reid G; Chatfield M; Armstrong NJ; Yan TD; Vardy J; Clarke S; van Zandwijk N; McCaughan B
J Thorac Oncol; 2011 Nov; 6(11):1923-9. PubMed ID: 22011651
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.
Stahel RA; Riesterer O; Xyrafas A; Opitz I; Beyeler M; Ochsenbein A; Früh M; Cathomas R; Nackaerts K; Peters S; Mamot C; Zippelius A; Mordasini C; Caspar CB; Eckhardt K; Schmid RA; Aebersold DM; Gautschi O; Nagel W; Töpfer M; Krayenbuehl J; Ribi K; Ciernik IF; Weder W
Lancet Oncol; 2015 Dec; 16(16):1651-8. PubMed ID: 26538423
[TBL] [Abstract][Full Text] [Related]
4. Combined modality treatment for malignant pleural mesothelioma: a single-centre long-term survival analysis using extrapleural pneumonectomy.
Frick AE; Nackaerts K; Moons J; Lievens Y; Verbeken E; Lambrecht M; Coolen J; Dooms C; Vansteenkiste J; De Leyn P; Nafteux P
Eur J Cardiothorac Surg; 2019 May; 55(5):934-941. PubMed ID: 30535191
[TBL] [Abstract][Full Text] [Related]
5. Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma.
Shaikh F; Zauderer MG; von Reibnitz D; Wu AJ; Yorke ED; Foster A; Shi W; Zhang Z; Adusumilli PS; Rosenzweig KE; Krug LM; Rusch VW; Rimner A
J Thorac Oncol; 2017 Jun; 12(6):993-1000. PubMed ID: 28341225
[TBL] [Abstract][Full Text] [Related]
6. Outcome for patients with malignant pleural mesothelioma referred for Trimodality therapy in Western Australia.
Hasani A; Alvarez JM; Wyatt JM; Bydder S; Millward M; Byrne M; Musk AW; Nowak AK
J Thorac Oncol; 2009 Aug; 4(8):1010-6. PubMed ID: 19546819
[TBL] [Abstract][Full Text] [Related]
7. Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery.
Frischknecht L; Meerang M; Soltermann A; Stahel R; Moch H; Seifert B; Weder W; Opitz I
J Thorac Cardiovasc Surg; 2015 Jun; 149(6):1539-46.e1. PubMed ID: 25840756
[TBL] [Abstract][Full Text] [Related]
8. A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.
Kataoka Y; Yamamoto Y; Otsuki T; Shinomiya M; Terada T; Fukuma S; Yamazaki S; Hirabayashi M; Nakano T; Fukuhara S
Jpn J Clin Oncol; 2015 Jun; 45(6):562-8. PubMed ID: 25838292
[TBL] [Abstract][Full Text] [Related]
9. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial.
Flores RM; Krug LM; Rosenzweig KE; Venkatraman E; Vincent A; Heelan R; Akhurst T; Rusch VW
J Thorac Oncol; 2006 May; 1(4):289-95. PubMed ID: 17409872
[TBL] [Abstract][Full Text] [Related]
10. Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy.
Thieke C; Nicolay NH; Sterzing F; Hoffmann H; Roeder F; Safi S; Debus J; Huber PE
Radiat Oncol; 2015 Dec; 10():267. PubMed ID: 26715491
[TBL] [Abstract][Full Text] [Related]
11. Survival by Histologic Subtype of Malignant Pleural Mesothelioma and the Impact of Surgical Resection on Overall Survival.
Verma V; Ahern CA; Berlind CG; Lindsay WD; Shabason J; Sharma S; Culligan MJ; Grover S; Friedberg JS; Simone CB
Clin Lung Cancer; 2018 Nov; 19(6):e901-e912. PubMed ID: 30224273
[TBL] [Abstract][Full Text] [Related]
12. A feasibility study evaluating Surgery for Mesothelioma After Radiation Therapy: the "SMART" approach for resectable malignant pleural mesothelioma.
Cho BC; Feld R; Leighl N; Opitz I; Anraku M; Tsao MS; Hwang DM; Hope A; de Perrot M
J Thorac Oncol; 2014 Mar; 9(3):397-402. PubMed ID: 24445595
[TBL] [Abstract][Full Text] [Related]
13. Extrapleural pneumonectomy in the treatment of epithelioid malignant pleural mesothelioma: novel prognostic implications of combined N1 and N2 nodal involvement based on experience in 529 patients.
Sugarbaker DJ; Richards WG; Bueno R
Ann Surg; 2014 Oct; 260(4):577-80; discussion 580-2. PubMed ID: 25203873
[TBL] [Abstract][Full Text] [Related]
14. Pathological complete response in malignant pleural mesothelioma patients following induction chemotherapy: Predictive factors and outcomes.
Lau B; Kumar S; Yan T; Burn J; Kennedy C; McLean J; Boyer M; McCaughan B; Kao S
Lung Cancer; 2017 Sep; 111():75-78. PubMed ID: 28838403
[TBL] [Abstract][Full Text] [Related]
15. Systemic Therapy Use and Outcomes After Relapse from Preoperative Radiation and Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma.
Soldera SV; Kavanagh J; Pintilie M; Leighl NB; de Perrot M; Cho J; Hope A; Feld R; Bradbury PA
Oncologist; 2019 Jul; 24(7):e510-e517. PubMed ID: 30478189
[TBL] [Abstract][Full Text] [Related]
16. Persistent lung expansion after pleural talc poudrage in non-surgically resected malignant pleural mesothelioma.
Rena O; Boldorini R; Papalia E; Mezzapelle R; Baietto G; Roncon A; Casadio C
Ann Thorac Surg; 2015 Apr; 99(4):1177-83. PubMed ID: 25669666
[TBL] [Abstract][Full Text] [Related]
17. Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board.
Kao SC; Vardy J; Chatfield M; Corte P; Pavlakis N; Clarke C; van Zandwijk N; Clarke S
Clin Lung Cancer; 2013 Jan; 14(1):70-7. PubMed ID: 22658812
[TBL] [Abstract][Full Text] [Related]
18. Does surgery improve survival of patients with malignant pleural mesothelioma?: a multicenter retrospective analysis of 1365 consecutive patients.
Bovolato P; Casadio C; Billè A; Ardissone F; Santambrogio L; Ratto GB; Garofalo G; Bedini AV; Garassino M; Porcu L; Torri V; Pastorino U
J Thorac Oncol; 2014 Mar; 9(3):390-6. PubMed ID: 24518090
[TBL] [Abstract][Full Text] [Related]
19. Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest Group 0601 Trial).
Hasegawa S; Okada M; Tanaka F; Yamanaka T; Soejima T; Kamikonya N; Tsujimura T; Fukuoka K; Yokoi K; Nakano T
Int J Clin Oncol; 2016 Jun; 21(3):523-30. PubMed ID: 26577445
[TBL] [Abstract][Full Text] [Related]
20. Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma.
Lang-Lazdunski L; Bille A; Lal R; Cane P; McLean E; Landau D; Steele J; Spicer J
J Thorac Oncol; 2012 Apr; 7(4):737-43. PubMed ID: 22425923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
